An update from an ongoing clinical trial appears to have disappointed investors, but that's not actually warranted by the data.
News & Analysis: ArQule
ARQL earnings call for the period ending September 30, 2019.
The pharma company has wowed investors with solid clinical data multiple times this year.
ARQL earnings call for the period ending June 30, 2019.
These biotech stocks have at least quadrupled in just over six months this year.
The pharmaceutical pipeline shined, and the business doubled its cash position.
Investors are increasingly optimistic about the company.
A new day, a new batch of promising interim data from an early-stage clinical study.
The stock soared to its highest level in over 10 years on encouraging, early-stage clinical results.
Stocks were poised to ease lower on Friday morning.